1-3 of 3
Peter Lin
Close
Sort by
Journal Articles

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Dong-Wook Kim, MD, Dongho Kim, Soo-Hyun Kim, Hyun-Gyung Goh, Fabrizio Pane, Timothy Hughes, Jerald P. Radich, Peter Lin, Giuseppe Saglio, Susan Branford, Giovanni Martinelli, Simona Soverini, Andreas Hochhaus
Journal: Blood
Blood (2010) 116 (21): 3441.
https://doi.org/10.1182/blood.V116.21.3441.3441
Published: 2010
Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD
Journal: Blood
Blood (2008) 112 (11): 3187.
https://doi.org/10.1182/blood.V112.11.3187.3187
Published: 2008
Journal Articles

Soluble CD40 ligand induces endothelial dysfunction in human and porcine coronary artery endothelial cells

Changyi Chen, Hong Chai, Xinwen Wang, Jun Jiang, Md Saha Jamaluddin, Dan Liao, Yuqing Zhang, Hao Wang, Uddalak Bharadwaj, Sheng Zhang, Min Li, Peter Lin, Qizhi Yao
Journal: Blood
Blood (2008) 112 (8): 3205–3216.
https://doi.org/10.1182/blood-2008-03-143479
Published: 2008
Includes: Supplemental data